NAYA_OUT_1 [2025-04-28 06:34:18 -0400] 5276 Bytes | 1437 tokens | Cum: 1437 tkns (17.96% of 8k)
==========================================================================

We're scouting for winners today. Its 6:34 AM on Mon Apr 28, 2025 and I'm looking at NAYA Biosciences (NAYA) up to $2.34 from $2.03

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: NAYA Biosciences (NAYA)
IPO: 2020-11-13 (4 Years Ago)
Market Cap: $1,086,794
Shares Outstanding: 670,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body.

Here’s a list of headlines for NAYA Biosciences:

Apr-24-25 09:00AM - INVO Fertility Confirms New Nasdaq Trading Symbol of IVF
Apr-14-25 07:30PM - NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations Company Renamed INVO Fertility, Inc.
Mar-13-25 04:30PM - NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
Feb-25-25 08:00AM - NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
Feb-19-25 09:15AM - NAYA Biosciences Announces Nomination of New Board Members
Jan-13-25 09:15AM - NAYA Biosciences Announces Pricing of $9.5 Million Public Offering
Jan-06-25 08:30AM - NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody
Oct-31-24 09:00AM - NAYA Biosciences to Present Translational Insights to Support Phase I/IIa Clinical Trials for its GPC3-Targeting NK Engager Bispecific Antibody at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Oct-24-24 09:00AM - NAYA Biosciences Announces Initiation of Phase 1/2a Clinical Trial for its GPC3-targeted NK Engager Bispecific Antibody in Patients with Hepatocellular Carcinoma
Oct-21-24 09:00AM - INVO Bioscience Confirms Corporate Name Change and New Trading Symbol in Connection with Its Recent Merger with NAYA Biosciences
Oct-14-24 09:18AM - INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
Aug-14-24 09:00AM - INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
May-15-24 09:53PM - INVO Stock Earnings: INVO Bioscience Reported Results for Q1 2024
May-15-24 09:53PM 04:15PM - INVO Reports Record First Quarter 2024 Financial Results
May-14-24 07:34AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Apr-17-24 08:16AM - Why Is Invo Bioscience (INVO) Stock Up 85% Today?
Apr-16-24 09:53PM - INVO Stock Earnings: INVO Bioscience Reported Results for Q4 2023
Apr-16-24 09:53PM 04:59PM - INVO Reports Fourth Quarter and Full Year 2023 Financial Results
Jan-23-24 08:00AM - NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON)
Jan-17-24 08:00AM - INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
Dec-11-23 08:00AM - NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal
Dec-06-23 09:00AM - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK Bispecific Antibodies and Optimally Engineered Off-the-Shelf Natural Killer Cell Therapies

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for NAYA Biosciences (NAYA).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NAYA_OUT_3 [2025-04-28 06:34:18 -0400] 933 Bytes | 276 tokens | Cum: 1715 tkns (21.44% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T15:13:00Z - INVO Fertility To Begin Trading Under New Nasdaq Ticker Symbol 'IVF'...
A2 - 2025-04-24T13:18:29Z - INVO Fertility confirms new Nasdaq trading symbol of "IVF" (NASDAQ:NAYA)...
A3 - 2025-04-15T12:05:00Z - NAYA Biosciences spins off cancer drug business 6 months after INVO merger...
A4 - 2025-04-15T09:19:09Z - Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Applied D...
A5 - 2025-04-15T07:11:10Z - NAYA Biosciences announces strategic decision to separate fertility and oncology...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NAYA_OUT_5 [2025-04-28 06:34:19 -0400] 1181 Bytes | 312 tokens | Cum: 2029 tkns (25.36% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**INVO Fertility To Begin Trading Under New Nasdaq Ticker Symbol 'IVF'**Date: 2025-04-24Source: {'uri': 'nasdaq.com', 'dataType': 'news', 'title': 'NASDAQ Stock Market'}URL: https://www.nasdaq.com/articles/invo-fertility-begin-trading-under-new-nasdaq-ticker-symbol-ivf(RTTNews) - INVO Fertility, Inc. (NAYA), Thursday announced that it will begin trading under the new Nasdaq ticker symbol "IVF" at the market open on April 28, 2025, as part of its strategic rebranding and business realignment.

The company, previously known as NAYA Biosciences, said the symbol change reflects its renewed focus on fertility care following the separation of its oncology and fertility operations, first announced on April 14, 2025.

INVO confirmed that the CUSIP number for its common stock will remain unchanged.

"Our new Nasdaq ticker symbol of 'IVF' reflects our go-forward business concentration on the f

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_7 [2025-04-28 06:34:19 -0400] 1181 Bytes | 269 tokens | Cum: 2300 tkns (28.75% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): ertility care market," said Steve Shum, CEO of INVO Fertility. "We're focused on building, acquiring, and operating fertility clinics, and helping more people access affordable reproductive services."

The change aligns with INVO's mission to expand access to assisted reproductive technologies or ART in the U.S., particularly through its proprietary INVOcell device and intravaginal culture or IVC procedure, a more affordable and intimate alternative to traditional IVF.

The rebranding comes at a time when national attention on fertility access is growing, including a recent executive order from the U.S. President aimed at reducing the cost of IVF and expanding availability.

INVO currently operates two INVO Centers and one IVF clinic in the U.S. and continues to distribute its INVOcell technology to third-party fertility providers.

Currently, NAYA is trading at $2.00 up by 4.60 percent

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_9 [2025-04-28 06:34:20 -0400] 432 Bytes | 114 tokens | Cum: 2416 tkns (30.20% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_11 [2025-04-28 06:34:21 -0400] 537 Bytes | 151 tokens | Cum: 2569 tkns (32.11% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-01-16 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 14, 2025, NAYA Biosciences, Inc., a Nevada corporation (the Company), consummated a public offering (the Offering) of 13,615,171 units (Units), each consisting of either one share of common stock, par value $0.000...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NAYA_OUT_13 [2025-04-28 06:34:22 -0400] 1181 Bytes | 302 tokens | Cum: 2873 tkns (35.91% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement.

On January 14, 2025, NAYA Biosciences, Inc., a Nevada corporation (the Company), consummated a public offering (the Offering) of 13,615,171 units (Units), each consisting of either one share of common stock, par value $0.0001 per share (the Common Stock), or one pre-funded warrant to purchase one share of Common Stock (Pre-Funded Warrants) in lieu thereof, and one warrant to purchase one share of Common Stock at an offering price of $0.70 per Unit. The warrants are exercisable from and after the date of their issuance and expire on the five-year anniversary of such date, at an exercise price of $0.70 per share of Common Stock. Each Pre-Funded Warrant is immediately exercisable at an exercise price of $0.0001 per share and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In connection with

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_15 [2025-04-28 06:34:23 -0400] 1181 Bytes | 274 tokens | Cum: 3149 tkns (39.36% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): the Offering, the Company entered into a securities purchase agreement (the Purchase Agreement) with certain institutional investors who purchased Units in this Offering.

The securities issued in the Offering were offered pursuant to the Companys registration statement on Form S-1, as amended (File No. 333-283872) (the Registration Statement), initially filed by the Company with the Securities and Exchange Commission (the SEC) under the Securities Act of 1933, as amended (the Securities Act), on December 17, 2024 and declared effective on January 13, 2025.

The Company closed the Offering on January 14, 2015, raising gross proceeds of approximately $9.5 million before deducting placement agent fees and other offering expenses payable by the Company.

The Company intends to utilize (i) up to $2,500,000 of the net proceeds to fund the second installment of the purchase price for the Wis

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_17 [2025-04-28 06:34:24 -0400] 1181 Bytes | 280 tokens | Cum: 3431 tkns (42.89% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): consin Fertility Institute; (ii) $4,000,000 to redeem 4,000 shares of the Companys Series C-2 preferred stock with a stated value of $4,000,000; (iii) up to $1,950,000 towards outstanding debt obligations that are or will become payable upon completion of the Offering and that the Company does not otherwise restructure or refinance, and (iv) the balance of the net proceeds of the Offering for clinical trials, product development, marketing, strengthening the corporate management team, working capital, and general corporate purposes.

Also in connection with the Offering, on January 13, 2025, the Company entered into a placement agency agreement (the Placement Agency Agreement) with Maxim Group LLC (the Placement Agent), pursuant to which (i) the Placement Agent agreed to act as lead placement agent on a best efforts basis in connection with the Offering, and (ii) the Company agreed to p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_19 [2025-04-28 06:34:24 -0400] 1181 Bytes | 271 tokens | Cum: 3704 tkns (46.30% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ay the Placement Agent an aggregate fee equal to 6.5% of the gross proceeds raised in the Offering (or 5.0% in the case of certain investors) and warrants to purchase up to 746,357 shares of Common Stock at an exercise price of $0.875 per share (the Placement Agent Warrants). The Placement Agent Warrants are exercisable at any time after the six-month anniversary of the closing date, from time to time, in whole or in part, until five (5) years from the commencement of sales of the securities in the Offering. Additionally, the Company reimbursed the Placement Agent for certain expenses and legal fees up to $90,000.

The Placement Agency Agreement and the Purchase Agreement contain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, the Placement Agent, or the investors, as the case may be and ot

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_21 [2025-04-28 06:34:25 -0400] 1181 Bytes | 263 tokens | Cum: 3969 tkns (49.61% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): her obligations of the parties.

Pursuant to the terms of the Purchase Agreements and the Placement Agency Agreements, the Company has agreed that for a period of up to ninety (90) days from the closing of this Offering, that neither the Company nor any subsidiary may (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock equivalents or (ii) file any registration statement or prospectus, or any amendment or supplement thereto, in each case, subject to certain exceptions. The Company has also agreed not to effect or enter into an agreement to effect any issuance of Common Stock or Common Stock equivalents involving a Variable Rate Transaction, as defined in the Purchase Agreements, for a period of up to twelve (12) months following the closing of the Offering, subject to certain exceptions.

On January 14,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_23 [2025-04-28 06:34:26 -0400] 790 Bytes | 201 tokens | Cum: 4172 tkns (52.15% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): 2025, the Company entered into a warrant agency agreement (the Warrant Agent Agreement), with Transfer Online, Inc. appointing Transfer Online, Inc. as Warrant Agent for the Warrants.

In connection with the Offering, on January 13, 2025, the Company entered into a Class C-2 Preferred Stock Redemption Agreement (the Redemption Agreement) with Five Narrow Lane, LP (FNL), pursuant to which the Company agreed to purchase and acquire from FNL 4,000 shares of the Companys Series C-2 Convertible Preferr...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NAYA_OUT_25 [2025-04-28 06:34:33 -0400] 4934 Bytes | 1206 tokens | Cum: 5382 tkns (67.27% of 8k)
==========================================================================

This is our set of metrics for NAYA Biosciences.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+------------------------+
| Volume: 178,028 | Perf Month: -11.29% | Option/Short: No / No | Sales Y/Y TTM: 390.03% |
+--------------------+-----------------------+-----------------------+------------------------+
| Avg Volume: 58.84K | Perf Quarter: -61.81% | Short Float: 5.69% | ROE: -14358.50% |
+--------------------+-----------------------+-----------------------+------------------------+
| Rel Volume: 1.46 | Index: - | Short Ratio: 0.55 | ROI: -140.49% |
+--------------------+-----------------------+-----------------------+------------------------+
| RSI (14): 47.62 | Market Cap: 1.47M | Short Interest: 0.03M | Sales Surprise: 0.00% |
+--------------------+-----------------------+-----------------------+------------------------+
| ATR (14): 0.37 | Shs Outstand: 0.67M | Beta: 2.26 | EPS Surprise: 0.00% |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA20: 11.74% | Shs Float: 0.57M | Sales Q/Q: 481.38% | P/E: - |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA50: -25.29% | Inst Own: 16.31% | Sales past 5Y: - | Earnings: Apr 22 |
+--------------------+-----------------------+-----------------------+------------------------+
| SMA200: -71.13% | Insider Own: 13.80% | Employees: - | |
+--------------------+-----------------------+-----------------------+------------------------+
| Perf Week: 14.58% | Insider Trans: 0.00% | Debt/Eq: 3.96 | |
+--------------------+-----------------------+-----------------------+------------------------+

The next section covers any insider trading by NAYA Biosciences officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 2.2
Average Volume: 134598.16
30-Day High: 2.26
30-Day Low: 1.72
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of NAYA Biosciences (NAYA).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about NAYA Biosciences.

2) MARKET_SCORE[]
This conversation was initiated because NAYA is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NAYA.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NAYA could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NAYA to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of NAYA Biosciences.

11) ETHICAL_RATING[]
Rate NAYA Biosciences’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of NAYA Biosciences.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NAYA_IN_27 [2025-04-28 06:34:33 -0400] 126 Bytes | 29 tokens | Cum: 5656 tkns (70.70% of 8k)
==========================================================================

====================================
[2025-04-28 06:34:33] # Analysis Completed
Elapsed Time: 16.35 seconds